Citius rises as lymphoma drug shows benefit in patients before CAR-T therapy

Shares of drugmaker Citius Oncology CTOR.O rise 1.89% to $1.08

Co says early data shows its drug Lymphir may benefit patients with aggressive lymphoma, when administered before CAR-T therapy

 High-risk diffuse large B-cell lymphoma is a fast‑growing blood cancer

Co says 86% of 14 patients showed improvement after a single Lymphir dose administered before CAR-T, with over half reaching complete remission

 Mild side effects were reported; all patients were able to proceed with CAR-T, co says

Lymphir was approved in 2024 to treat certain adult patients with a group of rare blood cancers that affects the skin

Shares down ~13% in 2025